EZH2 and breast carcinoma: In the targeted treatment of breast cancer, EZH2-mediated silencing of protein phosphatase 2 regulatory subunit B leads to drug tolerance and acquired resistance to anti-human epidermal growth factor receptor 2 therapy.94